Myelodysplastic Syndrome (MDS) Drugs Market Size and Forecast 2024-2033|Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV

Overview and Scope

Myelodysplastic syndrome (MDS) drugs are medications used to treat myelodysplastic syndrome, a collection of several bone marrow illnesses in which the bone marrow fails to create enough healthy blood cells. They work by helping to restore normal gene function in bone marrow cells and produce more red blood cells.

Sizing and Forecast

The myelodysplastic syndrome (mds) drugs market size has grown strongly in recent years. It will grow from $3.23 billion in 2023 to $3.47 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%.  The  growth in the historic period can be attributed to aging population, advancements in targeted therapies, clinical trials, increased awareness.

The myelodysplastic syndrome (mds) drugs market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%.  The growth in the forecast period can be attributed to genomic research, immunotherapies, global expansion of healthcare, biomarker identification. Major trends in the forecast period include personalized medicine, combinatorial therapies, symptom management, data sharing and collaboration.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Segmentation & Regional Insights

The myelodysplastic syndrome (mds) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy; Immunomodulatory Drugs

2) By Route Of Administration: Oral; Parenteral

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia; Refractory Anemia; Refractory Anemia With Ringed Sideroblasts

4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2023. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Major Driver Impacting Market Growth

Rising exposure to cancer treatments, such as chemotherapy and radiation, is expected to boost the growth of the myelodysplastic syndrome (MDS) drug market going forward. Chemotherapy refers to using medications to eradicate cancer cells and radiation refers to a cancer treatment that uses high radiation doses to kill cancer cells and reduce tumors. Chemotherapy medications and radiation therapy harm the bone marrow’s stem cells, which are in charge of making new blood cells; this damaging effect disturbs the natural balance of cell creation and results in the onset of MDS. Myelodysplastic syndrome (MDS) drugs offer several benefits in managing and treating MDS, a group of disorders characterized by abnormal production of blood cells in the bone marrow. For instance, according to ESTRO-HERO (Health Economics in Radiation Oncology) analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, based on projected cancer distributions in 2025, there is an expected 16% increase in the number of radiotherapy treatment courses. Therefore, rising exposure to cancer treatments, such as chemotherapy and radiation, is driving the growth of the myelodysplastic syndrome (MDS) drugs market.

Key Industry Players

Major players in the myelodysplastic syndrome (mds) drugs market are  Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

The myelodysplastic syndrome (mds) drugs market report table of contents includes:

1. Executive Summary

2. Myelodysplastic Syndrome (MDS) Drugs Market Characteristics

3. Myelodysplastic Syndrome (MDS) Drugs Market Trends And Strategies

4. Myelodysplastic Syndrome (MDS) Drugs Market – Macro Economic Scenario

5. Global Myelodysplastic Syndrome (MDS) Drugs Market Size and Growth

.

.

.

26. South America Myelodysplastic Syndrome (MDS) Drugs Market

27. Brazil Myelodysplastic Syndrome (MDS) Drugs Market

28. Middle East Myelodysplastic Syndrome (MDS) Drugs Market

29. Africa Myelodysplastic Syndrome (MDS) Drugs Market

30. Myelodysplastic Syndrome (MDS) Drugs Market Competitive Landscape And Company Profiles

Top Major Players:

• Bristol Myers Squibb
• Otsuka Pharmaceutical Co. Ltd
• Teva Pharmaceutical Industries Ltd
• Dr. Reddy’s Laboratories Ltd
• Mylan NV

Explore the trending research reports from TBRC:

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model